Despite the TGA’s instruction for Reckitt Benckiser to withdraw Nurofen (ibuprofen) TV advertisements over claims the product provided “targeted pain relief,” the drug manufacturer says messages that Nurofen “works at the site of pain,” will stay.
A statement released today by Reckitt Benckiser said they did not agree with a number of sanctions requested by the TGA’s Complaints Resolution Panel (CRP) and the company was preparing a response to them.
“Nurofen advises that consumers will continue to see the familiar branding of Nurofen target and messages of Nurofen working at the site of pain,” the statement read.
Reckitt said the branding would include TGA approved claims on packs that Nurofen provided targeted relief from pain.
Nurofen said the TGA had no questions regarding the...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.